BioCardia, Inc. BCDA

BioCardia announces FDA confirmation of Helix Transendocardial Delivery Catheter meeting minutes supporting follow-on De Novo pre-submission for approval. FDA confirmation advances Helix catheter toward De Novo approval and strengthens BioCardia's regulatory and commercialization path.

BioCardia held its Q2 2026 earnings call to discuss quarterly financial results and business updates. Quarterly earnings calls disclose financial performance and strategy that can moderately shift investor sentiment.

BioCardia Inc secured regulatory wins in Japan and the US, as highlighted in its Q2 2026 earnings call. Regulatory wins in Japan and the US position BioCardia for expanded market access and revenue growth.

BioCardia, Inc. held its Q2 2026 earnings call covering quarterly financial results, operational updates, and forward outlook. Quarterly earnings call delivers financial metrics and guidance that can shift near-term investor sentiment and valuation.

BioCardia reported second quarter 2026 business highlights and financial results. Quarterly earnings and highlights deliver operational and financial updates that moderately shape near-term market views and stock movement.

BioCardia issues letter to stockholders outlining 2026 priorities and strategic opportunities. Forward-looking priorities letter can shift investor sentiment and signal medium-term company direction.

BioCardia, Inc. secures $4.4 million in financing. Capital infusion supports near-term operations for BioCardia without shifting core trajectory or market position.

BCDA stock surged over 50% on positive clinical trial data for its lead cell therapy showing improved outcomes in heart failure patients, driving strong investor buying. Positive pivotal trial data for core therapy directly lifts valuation and future revenue outlook.

BioCardia shares rally after FDA supports regulatory path for heart failure therapy. FDA regulatory support advances BioCardia heart failure therapy toward potential approval and revenue.

FDA confirms CardiAMP HF II trial may support premarket approval of CardiAMP Cell Therapy for Ischemic HFrEF. FDA confirmation on pivotal trial design raises odds of therapy approval and materially improves BioCardia commercial prospects.

BioCardia received Japan PMDA Record of Advice supporting regulatory submission for CardiAMP Cell Therapy approval to treat ischemic heart failure. PMDA support advances CardiAMP toward Japanese approval and potential revenue growth.

BioCardia announced positive CardiAMP Chronic Myocardial Ischemia Trial results presented at EuroPCR showing durable gains in exercise tolerance and reduced angina frequency. Positive pivotal trial data for lead CardiAMP therapy supports regulatory progress and potential revenue growth.

BioCardia (BCDA) released its Q1 2026 earnings transcript covering quarterly financial results, operational updates and forward outlook for the company. Quarterly earnings release supplies financial metrics and guidance that can shift near-term investor sentiment and trading activity.

BioCardia Inc (BCDA) Q1 2026 earnings call highlighted breakthroughs in cardiac therapy development and related clinical progress. Breakthroughs in cardiac therapy signal major advancements likely to drive significant future growth and market gains for BioCardia.

BioCardia, Inc. held its Q1 2026 earnings call covering quarterly financial results, operational updates, and forward-looking plans for its biotherapeutic programs. Quarterly earnings call supplies financial results and pipeline updates that moderately affect near-term valuation and investor sentiment.

BioCardia, Inc. (BCDA) reported first quarter 2026 business highlights and financial results. Quarterly business highlights and financial results typically affect short-term market sentiment and financial performance for biotech firms.

BioCardia, Inc. (BCDA) and the FDA have aligned on regulatory clearance pathways for the Helix Transendocardial Delivery Catheter. FDA alignment on clearance pathways for the Helix catheter marks a key regulatory advancement that could expedite BioCardia's path to market and improve investor sentiment.

BioCardia, Inc. announces allowance of a Japanese patent for its proprietary Heart3D™ Fusion Imaging Software, enabling procedure planning and real-time navigation during CardiAMP Cell Therapy procedures. Japanese patent allowance bolsters BioCardia's intellectual property protection for key Heart3D software in CardiAMP therapy, enhancing competitive edge and international expansion potential.

BioCardia, Inc. (BCDA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) have aligned on the acceptability of CardiAMP clinical data to support regulatory approval for treating ischemic heart failure. PMDA alignment on CardiAMP data acceptability advances regulatory approval pathway in Japan, a key market expansion for BCDA's ischemic heart failure therapy.

BioCardia, Inc. (BCDA) filed a request for a meeting with the FDA to discuss an accelerated approval pathway for the CardiAMP® System in treating ischemic heart failure. Filing for FDA meeting on accelerated CardiAMP approval signals major regulatory progress that could accelerate market entry and reshape BioCardia's trajectory in heart failure therapy.

BioCardia, Inc. released Q4 2025 earnings call summary covering financial results, operational updates, and future outlook. Q4 2025 earnings summary provides critical financial performance data and strategic guidance likely to influence stock trajectory and investor sentiment.

BioCardia Inc (BCDA) Q4 2025 earnings call highlights promising clinical results amid ongoing developments. Promising clinical results in Q4 2025 earnings call represent major strategic progress likely to significantly boost investor sentiment and company trajectory.

BioCardia, Inc. (BCDA) reported 2025 business highlights and financial results. Annual business highlights and financial results disclosure moderately influences financial performance and investor sentiment.

BioCardia announces FDA acceptance of its Pre-Submission Approval Package for the Helix Transendocardial Delivery Catheter. FDA acceptance advances regulatory pathway for a key delivery catheter, potentially accelerating approvals and improving BioCardia's competitive position.

BioCardia presented late-breaking echocardiography clinical results from the CardiAMP HF Trial at the Technology and Heart Failure Therapeutics (THT) conference. Late-breaking clinical trial results presentation at a major heart failure conference can drive significant investor interest and validate BioCardia's therapeutic pipeline.

BioCardia, Inc. has filed a pre-submission with the FDA for the Helix™ Transendocardial Delivery Catheter, aimed at delivering therapeutic and diagnostic agents directly to the heart. This catheter is designed to enhance treatment options for patients with various cardiac conditions, potentially improving outcomes in heart therapies. The FDA pre-submission for a new delivery catheter could significantly impact BioCardia's market position and product offerings in the cardiac treatment space.

BioCardia, Inc. announced that late-breaking echocardiography results from the CardiAMP HF Trial will be presented at the Technology and Heart Failure Therapeutics (THT) conference. These results are expected to provide insights into the efficacy of their CardiAMP cell therapy for heart failure patients, potentially influencing future treatment protocols and market interest in the therapy. The presentation of significant trial results could lead to major strategic moves and shifts in market dynamics for BioCardia.

BioCardia, Inc. announced that its cell therapy for ischemic heart failure will advance to a formal clinical consultation with Japan's Pharmaceuticals and Medical Devices Agency (PMDA). This step is crucial for the company's efforts to gain regulatory approval and expand its market presence in Japan, potentially enhancing treatment options for patients with heart failure. Advancing to formal clinical consultation with the PMDA is a significant regulatory milestone that could greatly influence BioCardia's market trajectory and investor sentiment.

BioCardia, Inc. (BCDA) is set to present at the December 2025 CSI Focus Devices in Heart Failure Congress, highlighting its commitment to advancing treatments for heart failure. The presentation is expected to showcase the company's innovative approaches and developments in the field, potentially attracting attention from industry professionals and investors. The presentation at a significant congress may enhance BioCardia's visibility and influence its competitive positioning in the heart failure market.

BioCardia, Inc. has appointed Farhan Shahab as Vice President of Quality, aiming to enhance its quality management systems and regulatory compliance. Shahab brings over 20 years of experience in quality assurance and regulatory affairs, having held leadership roles in various medical device companies. His expertise is expected to support BioCardia's commitment to delivering high-quality products and advancing its clinical programs. The addition of a seasoned professional in quality management may positively influence operational efficiency and product quality.